BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs7903146, PTEN, Angiogenesis, Lung cancer, Endothelial cell, Anticancer prodrugs)
Bookmark Forward

QuickView for everolimus (compound)


Genetic Markers

Most Correlated Genes

  1. DHRS2
  2. CRIP1
  3. MUC4
  4. MAL
  5. RHCG
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. regulation of nitrogen compound metabolic process
  2. cytosol
  3. organic cyclic compound binding
  4. heterocyclic compound binding
  5. cell periphery
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Blood from relapsed refractory acute lymphoblastic leukemia patients treated with everolimus
  2. Breast tumors of mice injected with breast cancer 4T1 cells and treated with RAD001
  3. Clear cell carcinoma of kidney 786-O cells treated with mTOR inhibitor Everolimus
  4. Hepatocellular carcinomas treated with PI3K/mTOR inhibitors
  5. Acute myelogenous leukemia cells expressing activated NRAS treated with RAS pathway inhibitors
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701).
  2. The treatment of aggressive prolactinomas with everolimus.
  3. Preclinical Evaluation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Via a Long-Term Rabb…
  4. Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with Cance…
  5. Tip-concentrated microneedle patch delivering everolimus for therapy of multiple sclerosis.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Dose EScalation Induction of EvERolimus
  2. Everolimus Aging Study
  3. Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
  4. Palbociclib With Everolimus + Exemestane In BC
  5. Pharmacokinetic of Everolimus and Atorvastatin Co-administration
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.